Abstract: A secondary battery according to an embodiment of the present disclosure includes an electrode assembly to which an electrode lead is attached; a case accommodating the electrode assembly so that a portion of the electrode lead is exposed to the outside; a sealing portion formed in the case to seal the electrode assembly; and a lead film covering a portion of an outer surface of the electrode lead and interposed between the electrode lead and the sealing portion, wherein the electrode lead includes a first region not corresponding to the lead film and exposed to the outside of the case, a second region corresponding to the lead film, and a third region not corresponding to the lead film and not exposed to the outside of the case, wherein a separation groove may be located in the third region.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: A method for counting coughs is provided. The method includes acquiring a plurality of onset signals from the sound signal, wherein the onset signal has a predetermined time length; acquiring a plurality of spectrograms corresponding to each of the plurality of onset signals; determining whether each of the acquired plurality of spectrograms represents a cough using a cough determination model; and calculating a number of coughs included in the sound signal based on a time point of a cough signal. The cough signal is an onset signal corresponding to one spectrogram determined to represent the cough. When a time interval between a first time point of a first cough signal and a second time point of a second cough is within a reference time interval, the first cough signal and the second cough signal are regarded as one cough signal at the first time point.

Abstract: A display device includes a substrate including a display area and a non-display area disposed near the display area, a plurality of pixels disposed in the display area, a plurality of signal lines disposed on the substrate and connected to the pixels, and a pad portion disposed in the non-display area and including a plurality of pads. The signal lines include a first crack detecting line connected to a first test voltage pad and a first pad at a first node, connected to a second pad at a second node, and extending around the non-display area between the first node and the second node, as well as a first data line including a first end connected to a first transistor connected to the first crack detecting line at the second node, and a second end connected to corresponding pixels from among the plurality of pixels.

Abstract: A method of obtaining urination information and a device thereof are proposed. The method includes obtaining one or more first feature data by using first sound data, obtaining a urine volume determination value by using the one or more first feature data and a pre-trained urine volume determination model, obtaining a urine flow rate determination value by using the one or more first feature data and a pre-trained urine flow rate determination model, and obtaining urine flow rate information by reflecting a ratio of an estimated urine volume calculated based on the urine flow rate determination value and the urine volume determination value to the urine flow rate determination value.

Abstract: According to one aspect of the invention, there is provided a method for calculating information on urination. The method includes the steps of acquiring a sound signal related to urination of a user, calculating a urination parameter related to an effective value (or urination parameters related to an effective value and a spectral centroid) from the acquired sound signal, and estimating a urine flow rate of the user with reference to the calculated urination parameter.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: A manufacturing method of a home appliance including a hairline according to disclosed embodiment includes forming at least one plating layer on the base material, processing the transverse hairline on the upper surface of the plating layer by tilting the hairline processing wheel at a predetermined angle, and forming a coating layer on the hairline.

Abstract: The present disclosure provides a method and apparatus for determining coupling and decoupling positions between trains. In at least one embodiment, the present disclosure provides a method performed by an apparatus for determining coupling and decoupling positions between trains, the method comprising collecting performance data, simulation data, and real-time data, calculating a first parameter and a second parameter, and determining the coupling and decoupling positions between the trains.

Abstract: Provided are: a pharmaceutical composition for treating myeloid leukemia (AML), and a method for treating acute myeloid leukemia using same, the pharmaceutical composition comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof, and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.

Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.

Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.

Abstract: Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Abstract: A content sharing method includes: selecting, by a content sharing terminal, content; transmitting, by the content sharing terminal, identification information of the selected content to an external device; and reproducing, by the content sharing terminal, the selected content while the external device is reproducing the selected content based on the identification information.

Abstract: A home appliance includes a hairline. A manufacturing method for a home appliance including a hairline includes forming at least one plating layer on a base material; processing a transverse hairline on an upper surface of a plating layer by tilting a hairline processing wheel at a predetermined angle, and forming a coating layer on the hairline. A home appliance having corrosion resistance and anti-fingerprint properties is produced while generating a transverse hairline. In addition, it is possible not to perform a separate plating after hairline processing.

Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.

Abstract: The present invention relates to an apparatus for managing voltage stability of an electrical power grid and a method therefor.